Cell and gene therapies are redefining the possibilities of veterinary medicine offering the potential to repair, replace, and restore biological function. With the first approvals expected as early as 2026, changemakers at the forefront of research and commercialisation explore the opportunities and hurdles that will define their path to clinical adoption.
- Clinical adoption – building veterinary trust and integrating into practice workflows
- Distribution – ensuring stability, scalability, and accessibility
Speaker(s):
Panellists

Linda Black
CEO
Gallant Therapeutics

Thomas Koch
Founder, CEO & CSO
eQcell Inc

Julia Loew
Chief Commercial Officer
MWI Animal Health
Time:
2:05pm - 2:35pm
Agenda Track No.:
Track 5
Session Type:
General Session (Presentation)